Strategic partnership ForteBio operates as a Sartorius business unit focused on biomolecular analysis with real-time interaction analysis, signaling alignment with large pharma and contract research organizations for accelerated biologics development and potential co-selling or integrated solutions.

Expansion opportunities Recent Sartorius growth activities, including new competence centers in Germany and expanded European facilities, suggest a regional push that could open cross-sell channels for ForteBio systems and services to nearby biotech hubs seeking advanced analytics and workflow solutions.

Tech-enabled selling The use of advanced tech like real-time biomolecular interaction analysis, combined with ForteBio software and services, presents a doorway to sell integrated hardware-software bundles, remote support, and ongoing service contracts to research institutions focusing on speed and accuracy.

Market positioning Position ForteBio as critical to early-stage biologics discovery and characterization, offering high-value capabilities (binding affinity, kinetics, concentration) to pharmaceutical R&D and manufacturing groups aiming to shorten timelines and reduce assay volumes.

Evidence of collaboration Recent Sartorius and partner activity, including Zeta Alpha collaboration and trade show demonstrations, indicates a favorable ecosystem for joint demonstrations and pilot programs that can be leveraged to win multi-site deployments and larger-scale contracts.